Back to Search Start Over

Development and extensive sequencing of a broadly-consented Genome in a Bottle matched tumor-normal pair.

Authors :
McDaniel JH
Patel V
Olson ND
He HJ
He Z
Cole KD
Schmitt A
Sikkink K
Sedlazeck FJ
Doddapaneni H
Jhangiani SN
Muzny DM
Gingras MC
Mehta H
Paulin LF
Hastie AR
Yu HC
Weigman V
Rojas A
Kennedy K
Remington J
Gonzalez I
Sudkamp M
Wiseman K
Lajoie BR
Levy S
Jain M
Akeson S
Narzisi G
Steinsnyder Z
Reeves C
Shelton J
Kingan SB
Lambert C
Bayabyan P
Wenger AM
McLaughlin IJ
Adamson A
Kingsley C
Wescott M
Kim Y
Paten B
Park J
Violich I
Miga KH
Gardner J
McNulty B
Rosen G
McCoy R
Brundu F
Sayyari E
Scheffler K
Truong S
Catreux S
Hannah LC
Lipson D
Benjamin H
Iremadze N
Soifer I
Eacker S
Wood M
Cross E
Husar G
Gross S
Vernich M
Kolmogorov M
Ahmad T
Keskus A
Bryant A
Thibaud-Nissen F
Trow J
Proszynski J
Hirschberg JW
Ryon K
Mason CE
Wagner J
Xiao C
Liss AS
Zook JM
Source :
BioRxiv : the preprint server for biology [bioRxiv] 2024 Oct 18. Date of Electronic Publication: 2024 Oct 18.
Publication Year :
2024

Abstract

The Genome in a Bottle Consortium (GIAB), hosted by the National Institute of Standards and Technology (NIST), is developing new matched tumor-normal samples, the first to be explicitly consented for public dissemination of genomic data and cell lines. Here, we describe a comprehensive genomic dataset from the first individual, HG008, including DNA from an adherent, epithelial-like pancreatic ductal adenocarcinoma (PDAC) tumor cell line and matched normal cells from duodenal and pancreatic tissues. Data for the tumor-normal matched samples comes from thirteen distinct state-of-the-art whole genome measurement technologies, including high depth short and long-read bulk whole genome sequencing (WGS), single cell WGS, and Hi-C, and karyotyping. These data will be used by the GIAB Consortium to develop matched tumor-normal benchmarks for somatic variant detection. We expect these data to facilitate innovation for whole genome measurement technologies, de novo assembly of tumor and normal genomes, and bioinformatic tools to identify small and structural somatic mutations. This first-of-its-kind broadly consented open-access resource will facilitate further understanding of sequencing methods used for cancer biology.<br />Competing Interests: Competing interests A.S. and K.S. are employees of Arima Genomics. L.F.P. from BCM, was sponsored by Genentech Inc until September 2023. F.J.S from BCM, received research support from Illumina, ONT and Pacbio. A.R.H and H-C.Y. are employees of Bionano Genomics and own stock shares and options of Bionano Genomics, Inc. V.W., K.K., J.R., and I.G. are employees of BioSkryb Genomics. M.S., K.B., B.R.L. and S.L. are employees of Element Biosciences. S.B.K., C.L., P.B., A.M.W., I.J.M., A.A., C.K., M.W., and Y.K. are employees and shareholders of PacBio, Inc. D.L., H.B., N.I., and I.S. are employees and shareholders of Ultima Genomics. S.E. and M.W. are employees of Phase Genomics. E.C., G.H., S.G., and M.V. are employees of KromaTiD, Inc, E.C. is also a shareholder. F.B., E.S., K.S., S.T. and S.C. are employees of Illumina, Inc. All other authors have no competing interests.

Details

Language :
English
ISSN :
2692-8205
Database :
MEDLINE
Journal :
BioRxiv : the preprint server for biology
Publication Type :
Academic Journal
Accession number :
39345378
Full Text :
https://doi.org/10.1101/2024.09.18.613544